EGFR antagonists for the treatment of diseases involving unwanted migration, proliferation, and / or metaplasia of retinal pigment epithelium (RPE) cells

EP4746970A1Pending Publication Date: 2026-05-27JONAS JOST B +3
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
JONAS JOST B
Filing Date
2024-09-12
Publication Date
2026-05-27

AI Technical Summary

Technical Problem

Current treatments for diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (RPE) cells, such as age-related macular degeneration (AMD), myopic macular degeneration, and proliferative vitreoretinopathy (PVR), are inadequate as they do not effectively address the non-vascular proliferative aspects of these conditions.

Method used

Development of pharmaceutical compositions containing EGFR blockers or agents that inhibit EGF receptor signaling, which are administered intravitreally to impede the proliferation of RPE cells, thereby reducing unwanted migration, proliferation, and metaplasia.

Benefits of technology

The use of EGFR blockers effectively reduces the processes contributing to the development and progression of AMD and other diseases characterized by RPE cell abnormalities, preserving vision and preventing further ocular damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024075555_20032025_PF_FP_ABST
    Figure EP2024075555_20032025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for use in the treatment of a disease involving unwanted migration, proliferation and / or metaplasia of retinal pigment epithelium (RPE) cells in a subject, wherein the pharmaceutical composition comprises at least one epidermal growth factor receptor (EGFR) antagonist.
Need to check novelty before this filing date? Find Prior Art